Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://clinicaltrials.gov/ct2/show/NCT02244541?term=Anavex&rank=1
Here’s the 2A CT trial for the 32 patients. Note the duration. 450 will take years as again Australia said it takes 3 years.
It took over 9 months for 32 patients. At that pace 450 will take how many years? I see why the options are good for 10 years for 50 percent enrollment.
Bad deal
FDA has approved several Alzheimer’s trials this year- last year and etc. it’s not the FDA.
10 years to get 50% enrollment is a joke. Apparently Australia delays are worse than reported. The Anavex board is horrible.
Lima on 8/30 you said.
placed an 8,000 share limit buy at $2.5. Lets see if the company wants my $20K and lets see if they drop this to $2.5
I said
Replies:
$2.50 will fill in time.
N2deep1 on 8/30/2018 3:37:58 PM
Now I will say again. $2.35 will fill and if not, Just wait.
Clint said all three trials would start in 2017. Calendar for Christmas perhaps. No credibility.
https://clinicaltrials.gov/ct2/show/NCT02244541?term=Anavex&rank=1
Here’s the 2A CT trial for the 32 patients. Note the duration. 450 will take years as again Australia said it takes 3 years. Clint was over zealous.
DEAD money. Trend is down and glad I sold a few thousand shares. Will consider buying later.
Agree. He is a finance guy. Thank you for stating the truth.
Read Misslings employment contract. Darn near impossible to fire.
Dead money 3 years.
Delays and dilution. CT 2A took 11 months to dose 32 patients in Australia. Australia self admits enrollment takes 3 years now.
450 enrollment with an average of 3 patients a month equals falling Share price. Even if it’s 9 a month that’s too long. How many locations are dosing? Before it was 5. This is going to cost which fits in with the constant dilution and delays.
I know this time will be different. LOL
Share price is inflated. Trial in Australia with all delays. Dilution. Be happy it’s @ $2.50.
$2.50 will fill in time. I have a buy order in for less. A lot less. Last purchase $1.98 sold for more. Holding to recycle again.
https://www.australianageingagenda.com.au/2018/07/10/head-of-dementia-initiative-talks-to-ccr/
3 years. I know Dr Mcdelays says it will be different this time.
He ran the last trial. I know this time will be different. LOL.
I just read DD - Delays and dilution. CT 2A took 11 months to dose 32 patients in Australia. Australia self admits enrollment takes 3 years now.
450 enrollment with an average of 3 patients a month equals falling Share price. Even if it’s 9 a month that’s too long. How many locations are dosing? Before it was 5. This is going to cost which fits in with the constant dilution and delays.
I know this time will be different. LOL
Looks like Cantor was wrong again.
Outcome is nevertheless the same as Anavex. The funding is derived from the backs of Longs in which some are no longer with us. RIP
Anavex has money in the bank and no debt.
Companies have filed Chapter 7 bankruptcy and come out with money in the bank and no debt.
AVXL has been a bad long term hold investment over last 5 years. Opportunity costs are great.
CEO comments “2018 is set to be a transformational year for the company and, already in the first quarter, we have made important progress in advancing our lead program, Vicinium™, for high-grade non-muscle invasive bladder cancer, or NMIBC,” said Stephen Hurly, president and chief executive officer of Eleven Biotherapeutics. “Our Phase 3 registration trial, the VISTA Trial, investigating Vicinium for patients with high-grade NMIBC, is progressing well and recently completed enrollment. We look forward to presenting three-month data from the trial in an oral presentation at the American Urological Association Annual Meeting on May 21st, a significant catalyst for the company and our Vicinium program.
CEOs being bullish is one thing. Transparent and specific is another.
Open label trial and they already have the results. I’ll take these odds.
The same could be said about Anavex 6. The filings said probable AD and Anavex participants started near same MMSE.
734 patients in 3 year study, 33% improved or stayed the same.
https://alzres.biomedcentral.com/articles/10.1186/alzrt210
Read the abstract
It's not a good time to add unless you like wasting money. Most of the technicals have been saying sell for a long time.
Anavex has competition. That's the point.
Fact Prothena directors have industry experience. That's the point.
False competition is stated in forward looking statements
This Quarterly Report on Form 10-Q includes forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our anticipated future clinical and regulatory milestone events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “expect” “should,” “forecast,” “could,” “suggest,” “plan” and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include, without limitation, statements regarding:
? our ability to generate any revenue or to continue as a going concern;
? our ability to successfully conduct clinical and preclinical trials for our product candidates;
? our ability to raise additional capital on favorable terms;
? our ability to execute our development plan on time and on budget;
? our products ability to demonstrate efficacy or an acceptable safety profile;
? our ability to obtain the support of qualified scientific collaborators;
? our ability, whether alone or with commercial partners, to successfully commercialize any of our product candidates that may be approved for sale;
? our ability to identify and obtain additional product candidates;
? intellectual property rights and protections;
? competition
False. They are directors listed as BOD. Anavex is a penny stock.
They are BOD and not SAB. Pick any baby bio and look at the directors.
Promis neuroscience and Prothena are two competitors to Anavex. Note the experience of the boards. BOD has like experience with CNS, Parkinson's and other CNS.
Pick almost any competitor and the one that is going to produce best drug has none or maybe one.
Creating a Board of Directors composed of great board members is vital to a company's success. (Source Great Board)
It states one board member outside industry not most.
Relevant Context
A great board member needs to have as much relevant context as possible in order to offer actionable and on-point advice.
Industry – While someone can be a great board member and not be from the same industry in which the company operates (sometimes it’s not a bad idea to have one board member who is from outside your industry, for perspective), it helps if most board members do have industry context in some form (customer, supplier, academic, etc.). It’s too hard to train a whole board on all the nuances of an industry, when decisions have to be made with alacrity using the best insights possible.
Jan1 2007 SP $3.10 and now $3.00. Money under pillow is a better investment. Anavex
False. See almost any other bios directors. Sp gives it a F. Lower SP is a fact.
None of the directors have extensive neurodegenerative disease, protein misfolding, Retts,Parkinson, neurobiology, neuronal dysfunction, Alzheimer's disease, monoclonal antibodies, cell therapy and etc experience
An osteopath?
Athanasios Skarpelos . Athanasios (Tom) Skarpelos, age 51, is a self-employed investor with 19 years of experience working with private and public companies. For the past 11 years, he has been focused on biotechnology companies involved in drug discovery and drug development projects. Mr. Skarpelos was engaged as a consultant to our Company for one year effective August 2, 2010. His experience has led to relationships with researchers at academic institutes in Europe and North America. Mr. Skarpelos is a founder of Anavex. He has served as a director of the Company since January 9, 2013.
Elliot Favus, MD. Elliot Favus, age 43, is Chief Executive Officer of Favus Institutional Research, a healthcare research firm serving institutional investors. He has been a healthcare equity research analyst on Wall Street since 2006, starting at Lazard Capital Markets and subsequently at Och-Ziff Capital Management Group. Prior to working on Wall Street, Dr. Favus was an Instructor in medicine at Mount Sinai School of Medicine in New York. He attended the University of Michigan (BA, 1996), the University of Chicago Pritzker School of Medicine (MD, 2001) and the NYU-Bellevue Hospital Internal Medicine Residency Program (2004). He is board-certified in Internal Medicine (2004) and has 10 years of basic science laboratory experience working on human genetics projects at Harvard Medical School, the University of Chicago and the University of Pittsburgh. He has served as a director of the Company since May 7, 2014.
Steffen Thomas, PhD . Steffen Thomas, age 52, has over 15 years of experience as a European patent attorney and is currently practicing at Epping Hermann Fischer, a major intellectual property law firm in Europe. Previously, Dr. Thomas worked for Japan-based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he worked for Nycomed Pharma, acquired by Takeda in 2011 for approximately USD $10 billion. Dr. Thomas’ legal practice covers drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement courts, and preparing opinions on patentability and infringement in the technical field of chemistry. Dr. Thomas has particular expertise in small molecule pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of Munich. He has served as a director of the Company since June 15, 2015.
Peter Donhauser, D.O. , Peter Donhauser, age 52, has more than 20 years of expertise in clinical research followed by practicing osteopathic medicine with an integrated medical approach in private practice since 2000. He worked at the University Hospital of Munich in the fields of geriatrics and neuromusculoskeletal diseases. During this time, he was a clinical trial investigator in multiple Phase 3 studies, including studies sponsored by Merck Sharp & Dohme/Merck, Boehringer Mannheim/Roche, Servier and Sanofi. He received his human medicine degree at the University of Munich and Doctor of Osteopathic
4
Medicine (D.O.) from the DAAO and EROP at the Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania . He has served as a director of the Company since February 8, 2017.
Claus van der Velden, PhD . Claus van der Velden, PhD, age 46, brings significant expertise in management, accounting, internal controls and risk management. Since July of 2011, he has served as corporate head of Management Accounting, Internal Audit and Risk Management at Stroeer SE & Co KGaA, a publicly listed German digital media company. Previously, Dr. van der Velden served as the Director of Corporate Business Controlling for the Nutrition & Health business unit at Cognis, a worldwide supplier of global nutritional ingredients and specialty chemicals. In this position, he was also a compliance representative and a member of the global leadership team. After the acquisition of Cognis by BASF, he was responsible for the management accounting processes of the BASF Nutrition & Health division, developing and producing mostly natural-source ingredients for the food and healthcare industries. Dr. van der Velden started his career as a strategy consultant at an international marketing and strategy consultancy firm. He studied in Kiel and Stockholm and received a degree in economics from the University of Kiel and later obtained his doctorate in business management from the WHU-Otto Beisheim School of Management where he also previously taught economics. He has served as a director of the Company since March 2, 2018.
Corporate Governance
Director Independence . The Board makes an affirmative determination that those members of its Board that serve as independent directors do not have any relationships with the Company and its businesses that would impair their independence at least annually. In connection with these determinations, the Board reviews information regarding transactions, relationships and arrangements involving the Company and its businesses and each director that it deems relevant to independence.
Let's do it.
Thanks Mongoose, I've read all of your posts to date and I like the way you think. I'm long avxl and really over extended avxl so I appreciate your thoughts. I'm N2deep.
Mongoose,
You placed a lot of confidence in Dr George Perry's opinion of Anavex. Since he is a director for Neurotrope now, has your opinion changed?
Single Sales day hits $25 billion. Impressive show of strength and infrastructure.